The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
A majority of adenocarcinomas and some squamous cell carcinomas showed moderate to strong cytoplasmic and membranous immunoreactivity. Remaining tumors were negative.
Most malignant cells showed membranous immunoreactivity. Malignant lymphomas and malignant gliomas were negative while a majority of skin, testicular, breast and renal cancers were weakly stained or negative.
Validation
One antibody yielding a staining pattern and there is no available gene/protein characterization data or the staining pattern is partly consistent with or contradicted by limited gene/protein characterization data
The multi-targeting antibody yielding a staining pattern consistent with gene/protein characterization data for all of the genes
